NCT01059656 - Phase II Pazopanib Study in Advanced Dermatofibrosarcomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Dermatofibrosarcomas of DARIER FERRAND(DFSP)

Interventions

DRUG

Pazopanib

Administration of pazopanib per os 800mg/ qd during 6 months until stable response according to primary endpoint, with 3 monthly successive examinations, and for a period of study not exceeding 18 months.

Trial Locations (1)

75010

Hôpital Saint-Louis - Service de Dermatologie (Pole POPS), Paris